

25th April, 2023

BSE Limited P.J. Towers, Dalal Street, Fort, Mumbai- 400 001 BSE scrip code: 543635 National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051 NSE symbol: PPLPHARMA

Dear Sir / Madam,

Sub: Reporting of Initial Disclosure to be made by an entity identified as a Large Corporate

In reference to Clause 3.1(a) of Chapter XII of the SEBI Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August, 2021, please find enclosed herewith Initial Disclosure in the prescribed format (as per Annexure A of the said Circular) for the year ended on 31st March, 2023.

You are requested to kindly take the above on record.

Yours Truly, For **Piramal Pharma Limited**

Tanya Sanish Company Secretary

Encl.: a/a



Sr.	Particulars	Details
No.		
1	Name of the company	Piramal Pharma Limited
2	CIN	U2429MH2020PLC338592
3	Outstanding borrowing of company as on	Rs. 1153.79 crores
	31 st March, 2022 (in Rs. Crores)	
4	Highest Credit Rating during the	AA
	previous FY along with name of the	CARE Ratings Ltd.
	Credit Rating Agency	
5	Name of Stock Exchange in which the	
	fine shall be paid, in case of shortfall in	BSE Ltd
	the required borrowing under the	
	framework	

Initial Disclosure to be made by an entity identified as a Large Corporate

We confirm that we are a Large Corporate as per the applicability criteria given under Chapter XII of SEBI Operational Circular dated 10th August, 2021.

Name: Ms. Tanya Sanish Company Secretary Contact no. 022-38023121

Place: Mumbai Date: 25th April, 2023 Name: Mr. Vivek Valsaraj Chief Financial Officer Contact no. 022-38023145